Early ‘in-lab’ use of levosimendan in patients with cardiogenic shock unsuitable for intra-aortic balloon pump counterpulsation | Zendy

Francesco Summaria | Zendy; Marina Mustilli | Zendy; Antonella Sette | Zendy; Chiara Lanzillo | Zendy; Enrico Romagnoli | Zendy

Open Access

Early ‘in-lab’ use of levosimendan in patients with cardiogenic shock unsuitable for intra-aortic balloon pump counterpulsation

Author(s) -

Francesco Summaria,

Marina Mustilli,

Antonella Sette,

Chiara Lanzillo,

Enrico Romagnoli

Publication year - 2014

Publication title -

therapeutic advances in cardiovascular disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.164

H-Index - 33

eISSN - 1753-9455

pISSN - 1753-9447

DOI - 10.1177/1753944713515310

Subject(s) - cardiogenic shock , medicine , levosimendan , intra aortic balloon pump , cardiology , myocardial infarction , balloon , percutaneous coronary intervention , intra aortic balloon pumping , shock (circulatory) , heart failure

Intra-aortic balloon pump counterpulsation is currently the most used mechanical assistance device for patients with cardiogenic shock due to acute myocardial infarction. However, a recently published meta-analysis and trial failed to confirm previous knowledge. We report the results of four patients with ST elevation myocardial infarction, complicated by cardiogenic shock unsuitable for intra-aortic balloon pump counterpulsation treated with early levosimendan infusion during primary percutaneous coronary intervention.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research